ClinicalTrials.gg
RecruitingNCT07082842Updated Apr 21, 2026

Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF

A Phase 3 interventional study of HEC585 and Placebo in Idiopathic Pulmonary Fibrosis (IPF), sponsored by Sunshine Lake Pharma Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
472
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.

Planned enrollment
8th of 60
472 · median 83
Started
2025
with 9 others
Phase 3
13 of 67
5 open now
Primary completion
2031-01
later than 28 of 28 live
Registered
52nd of 67
by date
Lead sponsor
5 of 67
Sunshine Lake Pharma Co., Ltd.

Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 8th largest by planned enrollment of the 60 interventional ones that give a count, is one of 10 that started in 2025, is one of 13 in phase 3, reaches primary completion later than 28 of the 28 other live ones, and was the 52nd registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

A multicenter, parallel, randomized, placebo (double-blind) and pirfenidone (open-label) controlled Phase III clinical trial to evaluate the efficacy and safety of HEC585 in patients with idiopathic pulmonary fibrosis (IPF)

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis (IPF)
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in this clinical study and sign the form before the study begins;
  2. When signing the informed consent form, the age should be between 40 and 80 years old (inclusive of 40 and 80), and gender is not restricted;
  3. Be diagnosed with IPF according to the diagnostic criteria of the IPF clinical practice guidelines jointly released by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society and the Latin American Thoracic Society in 2022 ; Chest high-resolution computed tomography (HRCT) examination (HRCT examination within 3 months before screening) or lung (if any) should be confirmed by central reading;
  4. The ratio of (FEV1) to forced vital capacity (FVC) at the screening period is ≥ 0.7;
  5. The percentage of FVC as a percentage of the normal predicted value at the screening period is ≥ 45%;
  6. The percentage of DLco ( [Hb] corrected) as a percentage of the normal predicted value at the screening period is ≥ 30%;
  7. Female or male subjects with potential fertility agree and commit to taking effective measures from the time of signing the informed consent form until 30 days after the last administration of the drug; at the same time, avoid sperm/egg collection, sperm/egg donation;
  8. According to the assessment by the investigator, the subjects are willing and able to comply with the requirements of the protocol and attend the visits.

Exclusion criteria

Exclusion Criteria:

  1. The researchers believe that the subjects experienced significant deterioration of IPF within the first three months of the randomization period.
  2. Other known causes of interstitial lung disease, such as exposure to the home or occupational environment, connective tissue diseases, drug toxicity, etc.
  3. Abnormalities in the lungs or chest that are and judged by the researchers to potentially affect the trial results.
  4. Within one month before randomization, any active infection requiring systemic treatment (such as oral or intravenous administration) in the form of activity (including bacterial, viral, parasitic or fungal infections).
  5. Expected to undergo lung transplantation during the course of the study.
  6. Expected survival period less than 6 months.
  7. History of malignant tumors within the previous 5 years (excluding localized cancers such as basal cell carcinoma).
  8. Moderate to severe liver dysfunction ( classification of grade B or C).
  9. Within six months before screening, history of unstable or deteriorating heart disease, including but not limited to the following conditions:

    1. Unstable angina pectoris;
    2. Myocardial infarction;
    3. Congestive heart failure requiring hospitalization or III/IV grade;
    4. Uncontrolled severe arrhythmia.
  10. Unable to perform the 6MWT or pulmonary function test, such as if the patient is mentally unstable and unable to cooperate, etc.;
  11. Allergic to any component of Ifinonate Hydrochloride Tablets (except the active ingredient, the include microcrystalline cellulose, pre-gelatinized starch, cross-linked povidone, povidone, dibutyl hydroxytoluene, colloidal silicon dioxide, magnesium stearate, polyvinyl alcohol, polyethylene glycol, talc and titanium dioxide) or pirfenidone tablets;
  12. The last administration of the study drug for other clinical trials occurred within 4 weeks before randomization or 5 half-lives (whichever is longer);
  13. Pregnant or breastfeeding;
  14. Within 3 months before screening, had a smoking history or was unwilling to maintain a smoking-free status during the study;
  15. Within 6 months before screening, frequently drank alcohol [average weekly alcohol consumption exceeding 21 units (1 unit = 360 mL of beer, or 150 mL of wine, or 45 mL of 40% alcohol spirits)];
  16. Had a history of drug abuse within 6 months before screening;
  17. Has a family or personal history of long syndrome;
  18. The investigator believes that the subject has conditions that may compromise their safety or compliance, significantly affect the pharmacokinetics of the drug, or prevent them from completing the study.
  19. During the screening period, liver function test values exceeded any of the following standards: total > 1.5 times the (ULN); or alanine aminotransferase > 2 times ULN;
  20. During the screening period, \< 45 mL/min/1.73 m2, calculated using the CKD-EPI (based on serum creatinine) formula ;
  21. At the time of screening, antibody or syphilis spirochete antibody test results were positive;
  22. At the time of screening, there was an uncontrolled virus infection (positive hepatitis B surface antigen, and hepatitis B DNA ≥ 2x102 IU/mL) or virus infection (positive anti-hepatitis C antibody and hepatitis C RNA);
  23. During the screening period, QTcF > 480 ms (using the Fridericia formula, QTcF = QT/RR\^0.33).
  24. Those who have previously taken isoniazidine hydrochloride;
  25. Within the first 4 weeks before randomization, used any of the following treatments:

    1. Any cytotoxic drugs or , including but not limited to azathioprine, cyclophosphamide, methotrexate, cyclosporine, etc.;
    2. Pirfenidone or nintedanib;
    3. > 15 mg/d prednisone or equivalent dose of other ;
    4. Strong inducers or inhibitors of , CYP2C8 or CYP2C19 (including but not limited to ritonavir, clarithromycin, aletris, carbamazepine, gemfibrozil, fluoxetine, fluvoxamine, etc.);
    5. Moderate, strong inhibitors or inducers of CYP1A2 (including but not limited to fluvoxamine, ciprofloxacin, enoxacin, etc.).
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
472 participants (estimated)

Study arms

  • Experimental
    HEC585

    Drug: HEC585

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Active comparator
    pirfenidone

    Drug: Pirfenidone

Interventions

  • DrugHEC585

    HEC585 tablet, taken once daily

  • DrugPlacebo

    HEC585 Simulation Board, taken once daily

  • Pirfenidone, taken three times a day

06

What researchers measure

Primary outcomes

  1. Change in FVC from baseline at 52 weeks (mL)

    Time frame: 52week

Secondary outcomes

  1. The interval (in days) from the start of the study until the first occurrence of any of the following clinical events (whichever occurs first) within 52 weeks

    Time frame: 52week

  2. The percentage of FVC relative to the predicted value (%FVC) compared to the baseline value changes

    Time frame: 52week

  3. The percentage of DLco(Hb-correction) relative to the expected value [%DLco(Hb-correction)] and the change from the baseline value

    Time frame: 52week

  4. The total walking distance of 6MWT(six minutes walk )test compared to the baseline value

    The longer the 6MWT distance is, the better the patient's disease condition is.

    Time frame: 52week

  5. The change in SGRQ(St George's Respiratory Questionnaire) score compared to the baseline

    A lower SGRQ score indicates a better disease condition for the subject.

    Time frame: 52week

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jan 2031, 62 months after the start.

Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's planned 62 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Jul 24, 2025
StartActual
Oct 27, 2025
Primary completionEst.
Jan 15, 2031
CompletionEst.
Feb 15, 2032
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07082842
Responsible party
Sponsor
First posted
Jul 24, 2025
Start date
Oct 27, 2025
Primary completion
Jan 15, 2031 (estimated)
Completion
Feb 15, 2032 (estimated)
Last update
Apr 21, 2026

Study contacts

huaping dai Doctor of Medicine(M.D.)
Contact
daihuaping@ccmu.edu.cn
010-84206278

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Yinfenidone

Start the discussion